Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy

Patent metadata

Field	Value
Publication number	US-10054590-B2
Application number	US-201313962522-A
Country	US
Kind code	B2
Filing date	Aug 8, 2013
Priority date	Jul 22, 2011
Publication date	Aug 21, 2018
Grant date	Aug 21, 2018

Abstract

The present invention relates to a method of identifying cancer subjects, in particular human patients, who are suitable for anti-lymphangiogenesis therapy to prevent tumor growth and tumor metastasis. The present invention also relates to a new approach, which uses nucleolin as a bait to search and screen for lymphangiogenesis inhibitors or cancer suppressors, which function in a manner that is analogous to endostatin. The invention is based upon the discovery that nucleolin is specifically expressed on lymphangiogenic vessels and functions as a specific receptor for endostatin, and thus is involved in the signal transduction pathway of endostatin as an anti-lymphangiogenesis inhibitor. The present invention also discloses that cell surface nucleolin on lymphatic endothelial cells is a biomarker for lymphangiogenic vessels, which could be used for the prediction of tumor metastasis.

First claim

We claim:

1. A method of treating a cancer subject having or suspected to have lymphatic metastasis, comprising the steps of:
a) determining the presence of cell surface nucleolin on lymphatic vessels in a cancer tissue sample or a tissue sample from lymph node adjacent to the cancer tissue from said subject, and
b) administering a therapeutically effective amount of endostatin to said subject if said subject is determined as positive for the presence of cell surface nucleolin on lymphatic vessels in the sample.

2. A method of preventing lymphatic metastasis in a cancer subject, comprising the steps of determining the presence of cell surface nucleolin on lymphatic vessels in a cancer tissue sample or a tissue sample from lymph node adjacent to the cancer tissue from said subject, and administering a therapeutically effective amount of endostatin to said subject if said subject is determined as positive for the presence of cell surface nucleolin on lymphatic vessels in the sample.

3. A method of preventing or inhibiting the proliferation and/or migration of lymphatic endothelial cells in a cancer subject, comprising the steps of determining the presence of cell surface nucleolin on lymphatic vessels in a cancer tissue sample or a tissue sample from lymph node adjacent to the cancer tissue from said subject, and administering a therapeutically effective amount of endostatin to said subject if said subject is determined as positive for the presence of cell surface nucleolin on lymphatic vessels in the sample.

4. The method of claim 1 , wherein the endostatin is in form of a conjugate.

5. The method of claim 4 , wherein the endostatin is covalently linked to a modifier capable of enhancing its half-life and/or biological activity.

6. The method of claim 5 , wherein the modifier is a PEG molecule.

7. The method of claim 6 , wherein the PEG molecule is covalently linked to the N-terminal amino group of the endostatin.

8. The method of claim 7 , wherein the PEG molecule has a molecular weight of 20-40 kD.

9. The method of claim 4 , wherein the endostatin is linked to a cytotoxic agent.

10. A method of treating a cancer subject after surgical removal of cancer lesion, wherein the cancer subject has negative lymph nodes without metastatic cancer cell, comprising:
(i) determining the presence of cell surface nucleolin on lymphatic vessels in a cancer tissue sample or a tissue sample from lymph node adjacent to the cancer tissue from said subject,
(ii) determining the likelihood of lymphatic metastasis of said subject, wherein the presence of cell surface nucleolin on lymphatic vessels in the cancer tissue sample or the lymph node tissue sample is indicative of high likelihood of lymphatic metastasis in said subject, and
(iii) administering a therapeutic effective amount of endostatin to said subject if said subject is determined as positive for the presence of cell surface nucleolin on lymphatic vessels in the cancer tissue sample or the lymph node tissue sample.

11. The method of claim 2 , wherein the endostatin is in form of a conjugate.

12. The method of claim 11 , wherein the endostatin is covalently linked to a modifier capable of enhancing its half-life and/or biological activity.

13. The method of claim 12 , wherein the modifier is a PEG molecule.

14. The method of claim 3 , wherein the endostatin is in form of a conjugate.

15. The method of claim 14 , wherein the endostatin is covalently linked to a modifier capable of enhancing its half-life and/or biological activity.

16. The method of claim 15 , wherein the modifier is a PEG molecule.

17. The method of claim 16 , wherein the PEG molecule is covalently linked to the Nterminal a amino group of the endostatin.

18. The method of claim 1 , further comprising, before the administering step, determining the susceptibility of the subject to endostatin therapy according to the presence or level of cell surface nucleolin on lymphatic vessels in the sample.

Assignees

• Univ Tsinghua
• Protgen Ltd

Inventors

• Luo Yongzhang
• Zhuo Wei
• Fu Yan
• Chang Guodong

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• G01N2333/515

  Angiogenesic factors; Angiogenin · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• G01N2800/56

  Staging of a disease; Further complications associated with the disease · CPC title

• C07K16/28

  against receptors, cell surface antigens or cell surface determinants · CPC title